PIGNATA, SALVATORE ANTONIO
 Distribuzione geografica
Continente #
EU - Europa 2.767
NA - Nord America 2.096
AS - Asia 1.168
SA - Sud America 366
AF - Africa 44
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 6
Totale 6.454
Nazione #
US - Stati Uniti d'America 2.040
RU - Federazione Russa 1.404
SG - Singapore 489
IT - Italia 341
CN - Cina 326
IE - Irlanda 313
BR - Brasile 306
SE - Svezia 252
DE - Germania 134
HK - Hong Kong 108
FR - Francia 101
VN - Vietnam 67
IN - India 56
PL - Polonia 55
FI - Finlandia 46
GB - Regno Unito 38
CA - Canada 28
AR - Argentina 23
BD - Bangladesh 21
NL - Olanda 19
JP - Giappone 18
ZA - Sudafrica 15
IQ - Iraq 14
AT - Austria 13
CI - Costa d'Avorio 12
BE - Belgio 11
ES - Italia 11
PK - Pakistan 11
MX - Messico 10
UZ - Uzbekistan 8
EC - Ecuador 7
TR - Turchia 7
CL - Cile 6
ID - Indonesia 6
LT - Lituania 6
PA - Panama 6
AU - Australia 5
AZ - Azerbaigian 5
CO - Colombia 5
CZ - Repubblica Ceca 5
MA - Marocco 5
VE - Venezuela 5
CR - Costa Rica 4
JM - Giamaica 4
PE - Perù 4
SA - Arabia Saudita 4
A1 - Anonimo 3
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
CH - Svizzera 3
PS - Palestinian Territory 3
PY - Paraguay 3
TN - Tunisia 3
UA - Ucraina 3
UY - Uruguay 3
BG - Bulgaria 2
BY - Bielorussia 2
GE - Georgia 2
IR - Iran 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MU - Mauritius 2
NG - Nigeria 2
NP - Nepal 2
OM - Oman 2
PH - Filippine 2
RO - Romania 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BS - Bahamas 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EU - Europa 1
GR - Grecia 1
HU - Ungheria 1
JO - Giordania 1
KE - Kenya 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
QA - Qatar 1
SR - Suriname 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.454
Città #
Ashburn 385
Moscow 383
Dublin 311
Singapore 301
Chandler 295
Dallas 218
Nyköping 176
San Jose 148
Hong Kong 107
Beijing 95
Munich 67
The Dalles 60
Princeton 53
Warsaw 52
Messina 48
Los Angeles 41
Medford 41
Lauterbourg 39
Dearborn 35
Des Moines 35
Bremen 33
New York 30
Jacksonville 29
Ann Arbor 27
São Paulo 25
Rome 24
Hyderabad 23
Helsinki 21
Ho Chi Minh City 20
Buffalo 18
Milan 17
Tianjin 17
Turku 16
Frankfurt am Main 15
Montreal 13
Orem 13
Redondo Beach 13
Santa Clara 13
Abidjan 12
Boardman 12
Cambridge 12
Hanoi 12
Jinan 12
Brussels 11
Council Bluffs 11
Kameido 10
London 10
Denver 8
Dong Ket 8
Düsseldorf 8
Falls Church 8
Nanjing 8
Palermo 8
Pune 8
Shenyang 8
Tokyo 8
Vienna 8
Belo Horizonte 7
Guangzhou 7
Johannesburg 7
Nuremberg 7
Porto Alegre 7
Rio de Janeiro 7
Shenzhen 7
Stockholm 7
Tashkent 7
Wilmington 7
Atlanta 6
Boston 6
Brasília 6
Chennai 6
Curitiba 6
Fuzhou 6
Hebei 6
Nanchang 6
Redwood City 6
Seattle 6
Shanghai 6
Vittoria 6
West Jordan 6
Brooklyn 5
Haiphong 5
Hangzhou 5
Phoenix 5
Santa Domenica 5
Sorocaba 5
Taizhou 5
Toronto 5
Baghdad 4
Baku 4
Bexley 4
Blumenau 4
Catania 4
Changsha 4
Dhaka 4
Faisalabad 4
Houston 4
Jakarta 4
Leeds 4
Mexico City 4
Totale 3.675
Nome #
EMIAGENESIA TIROIDEA, MORBO DI BASEDOW-GRAVES E CARCINOMA DIFFERENZIATO DELLA TIROIDE: UN’ASSOCIAZIONE MOLTO RARA. 326
99mTc-Methoxy-Isobutyl-Isonitrile Scintigraphy Is a Useful Tool for Assessing the Risk of Malignancy in Thyroid Nodules with Indeterminate Fine-Needle Cytology 275
A Single Centre Experience with 223-Radium-Dichloride ((RaCl2)-Ra-223) Therapy 201
Peptide Receptor Radionuclide Therapy and Somatostatin 'cold' Analogues Therapy in the Treatment of GEP-NET Patients: Our Center’ Experience 201
Abnormal 99mTc-MIBI Uptakein left lung mimicking a neoplastic lesion in a young woman with nodular goiter. A rare pitfall of 99mTc-MIBI 199
223RA-dichloride use in patients affected by bone metastases from castration-resistant prostate cancer: single centre experience 192
99mTc-Methoxy-Isobutil-Isonitrile (MIBI) scintigraphy is an useful and cost-effective tool for assessing the risk of malignancy in thyroid nodules with indeterminate fine needle cytology (FNAC) 191
Association of parathyroid carcinoma and thyroid disorders: A clinical review 191
99mTc-methoxy-isobutyl-isonitrile (MIBI) scintigraphy is an useful and cost-effective tool for assessing the risk of malignancy in thyroid nodules with indeterminate fine needle cytology (FNAC) 188
Prognostic Validity of Dual Tracer PET/CT in the PRRT Enrollment of GEP-NET Patients 183
Complete response in a pancreatic NEN with liver metastasis after PRRT in association with lanreotide autogel/depot 181
Complete Response in a Pancreatic Nen with Liver Metastasis after PRRT in association with Lanreotide Autogel/depot: Design of the Prelude Study 180
Usefulness of PET-CT scan in recurrent thyroid cancer 174
Braf V600E and 99m-TC MIBI scintigraphy are usefull diagnostic tools in identifying metastatic differentiated thyroid cancer patients refractory to radioiodine therapy. 172
Combined BRAFV600Eanalysis and99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation 171
Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy ina real life scenario 169
Differentiating malignant from benign thyroid nodules with indeterminate cytology by 99mTc-MIBI scan: A new quantitative method for improving diagnostic accuracy 166
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 163
Renal Function Evaluation in PRRT Retreatments 156
From clinical trials to the front line: Vinflunine for treatment of urothelial cell carcinoma at the National Cancer Institute of Naples 153
Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients 152
BRAFV600E and 99mTc-MIBI scintigraphy are usefull diagnostic tools in identifying metastatic differentiated thyroid cancer patients refractory to radioiodine therapy 151
Comparing radioiodine abdominal absorbed dose in differentiated thyroid cancer patients undergone thyroid remnant ablation in either levo-thyroxine withdrawal or after rhtsh stimulation 149
PRRT retreatments: renal function evaluation 149
Prognostic Validity of Dual Tracer PET/CT In The PRRT Enrollment of GEP-NET Patients 146
un caso di carcinoma delle paratiroidi associato ad adenoma autonomo omolaterale della tiroide 142
Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer? 138
The additional value of 18F-FDG PET and MRI in patients with glioma: A review of the literature from 2015 to 2020 130
Corrigendum: Pazopanib in metastatic renal cancer: A "real-world" experience at national cancer institute "Fondazione G. Pascale" [Front. Pharmacol., 7, 287, (2016)] doi: 10.3389/fphar.2016.00287 129
Is dual tracer PET/CT a prognostic biomarker in the PRRT enrollment of GEP-NET patients? 127
Pazopanib in metastatic renal cancer: A "real-world" experience at National Cancer Institute "Fondazione G. Pascale" 125
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223 123
Very early PSA response to abiraterone in mCRPC patients: A novel prognostic factor predicting overall survival 122
Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: The prospective observational scoop trial results 122
The sensitivity and positive predictive value (PPV) of I-131-post-therapy whole body scan is higher than serum Tg values in detecting metastases in early stage of differentiated thyroid cancer patients 120
Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario 118
Undetectable or low (< 1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients 114
Theranosticsin nuclear medicine and oncology 107
Post-operative radioiodine therapy (RaIT) as adjuvant therapy in low–intermediate risk differentiated thyroid cancer 92
Peptide receptor radionuclide therapy plus somatostatin analogues for a neuroendocrine tumour combined and maintenance treatment 62
Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose 60
Sequencing radium 223 (RA223) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the daily practice: Preliminary results from a retrospective study in Italian centers 60
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra 43
null 24
null 23
null 16
Totale 6.576
Categoria #
all - tutte 22.589
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.589


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 0 0 12
2021/2022355 6 35 6 7 21 10 8 28 5 39 48 142
2022/2023996 86 128 48 84 71 90 17 58 369 10 22 13
2023/2024243 20 26 13 28 24 42 16 12 0 27 5 30
2024/20251.106 12 30 18 51 78 38 34 209 261 80 141 154
2025/20263.233 222 177 244 140 250 663 399 456 420 176 39 47
Totale 6.576